Description
A next-generation synthetic peptide engineered as a unimolecular triple agonist at the GIP, GLP-1, and glucagon receptors. Actively studied in Phase 2/3 trials and an object of intense research interest.
A next-generation synthetic peptide engineered as a unimolecular triple agonist at the GIP, GLP-1, and glucagon receptors. Actively studied in Phase 2/3 trials and an object of intense research interest.
A next-generation synthetic peptide engineered as a unimolecular triple agonist at the GIP, GLP-1, and glucagon receptors. Actively studied in Phase 2/3 trials and an object of intense research interest.
| Strength | 5mg, 10mg, 20mg |
|---|